SPBC1271.07c Antibody

What is SPBC1271.07c and what is its functional role in fission yeast?

SPBC1271.07c is an uncharacterized N-acetyltransferase (EC 2.3.1.-) found in Schizosaccharomyces pombe (fission yeast). It belongs to the acetyltransferase family and has been localized to both the cytoplasm and nucleus. This protein has been studied in the context of the TSC (Tuberous Sclerosis Complex) pathway, suggesting potential involvement in cell growth regulation and signaling processes . While the precise function remains under investigation, its classification as an acetyltransferase suggests it may catalyze the transfer of acetyl groups to substrates, potentially influencing protein function through post-translational modifications.

What antibody options are currently available for SPBC1271.07c research?

Currently, the primary antibodies available for SPBC1271.07c are polyclonal antibodies raised in rabbits against antigens from Schizosaccharomyces pombe (strain 972/24843). These antibodies are typically:

• Antigen-affinity purified to enhance specificity

• Supplied in liquid form with preservatives (e.g., 0.03% Proclin 300)

• Formulated in buffer solutions containing 50% glycerol and phosphate-buffered saline (pH 7.4)

• Validated for applications including ELISA and Western blotting

Similar antibody development approaches have been used for related proteins in the SPBC1271 locus, such as SPBC1271.05c (AN1-type zinc finger protein) and SPBC1271.10c (uncharacterized MFS-type transporter) .

How can I determine the appropriate SPBC1271.07c antibody dilution for Western blot applications?

Determining the optimal antibody dilution requires systematic titration:

• Begin with a dilution range based on manufacturer recommendations (typically 1:500 to 1:5000)

• Prepare a dilution series (e.g., 1:500, 1:1000, 1:2000, 1:5000)

• Run identical samples on multiple gel lanes

• Process each membrane section with a different antibody dilution

• Compare signal-to-noise ratios across dilutions

For SPBC1271.07c antibodies specifically, consider:

• Starting with moderate dilutions (1:1000) for initial testing

• Including both wild-type samples and negative controls (deletion mutants if available)

• Evaluating specificity by checking for single bands at the expected molecular weight (~29-30 kDa for SPBC1271.07c)

• Testing different incubation times (1-hour vs. overnight at 4°C)

The optimal dilution provides clear specific bands with minimal background across multiple experimental replicates.

What are the recommended protocols for SPBC1271.07c protein detection by Western blotting?

Based on methodologies used with similar fission yeast proteins, the following Western blotting protocol is recommended for SPBC1271.07c detection:

Sample Preparation:

• Lyse cells with glass beads in lysis buffer [150 mM NaCl and 10 mM Tris-HCl (pH 7.0)] containing 0.5% Triton X-100 and 0.5% deoxycholate

• Add protease inhibitors (0.4 mM phenylmethylsulfonyl fluoride and 1× protease inhibitor cocktail)

• Load equal amounts of total proteins onto a 15% polyacrylamide gel

• Transfer to nitrocellulose membranes

Immunodetection:

• Block membrane with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary SPBC1271.07c antibody (1:1000 dilution) overnight at 4°C

• Wash membrane 3× with TBST (10 minutes each)

• Incubate with secondary antibody (anti-rabbit HRP-conjugated, 1:5000) for 1 hour at room temperature

• Wash membrane 3× with TBST

• Develop using ECL detection reagents

This protocol has been effective for detecting similar proteins in fission yeast, including those involved in the TSC pathway .

How can I validate the specificity of a SPBC1271.07c antibody?

Comprehensive validation requires multiple approaches:

• Genetic validation:

  • Compare wild-type vs. SPBC1271.07c deletion mutant samples

  • Test with overexpression strains (using vectors like pREP41 or pREP81)

  • Analyze point mutants with known amino acid substitutions

• Biochemical validation:

  • Pre-absorption test: Pre-incubate antibody with purified antigen before use

  • Peptide competition assay: Co-incubate antibody with increasing concentrations of immunizing peptide

  • Immunoprecipitation followed by mass spectrometry to confirm target identity

• Cross-reactivity assessment:

  • Test against related acetyltransferases in S. pombe

  • Check reactivity against homologs in other yeast species

  • Evaluate specificity across different genetic backgrounds

• Technical controls:

  • Include loading controls (e.g., anti-actin antibody)

  • Test multiple antibody lots if available

  • Compare with alternative antibodies if available

Document all validation results systematically to establish confidence in antibody specificity.

What approaches can be used to generate custom antibodies against specific domains of SPBC1271.07c?

For generating domain-specific SPBC1271.07c antibodies:

• Antigen design considerations:

  • Perform bioinformatic analysis to identify discrete functional domains within SPBC1271.07c

  • Select regions with high antigenicity and surface exposure

  • Avoid highly conserved regions if specificity between related proteins is required

  • Consider both peptide antigens (15-25 amino acids) and recombinant protein fragments

• Expression and purification strategies:

  Similar approaches have been successful for generating antibodies against Rhb1 in fission yeast

• Immunization protocols:

  • Select appropriate host species (rabbit for polyclonal; mouse for monoclonal)

  • Design immunization schedule with primary and multiple boost injections

  • Consider conjugating peptides to carrier proteins (KLH or BSA) to enhance immunogenicity

• Screening and purification methods:

  • For polyclonal antibodies: Affinity purification using immobilized antigen

  • For monoclonal antibodies: Hybridoma development and clone selection

  • Validate with ELISA against both immunizing antigen and full-length protein

These approaches have been successfully applied to generate antibodies against various fission yeast proteins involved in similar pathways .

How can SPBC1271.07c antibodies be utilized in studying protein-protein interactions within the TSC pathway?

SPBC1271.07c antibodies can be instrumental in dissecting protein-protein interactions through these methodologies:

• Co-immunoprecipitation (Co-IP) studies:

  • Immunoprecipitate SPBC1271.07c using specific antibodies

  • Analyze co-precipitated proteins by western blotting or mass spectrometry

  • Compare results between wild-type and TSC pathway mutants (e.g., tsc1Δ, tsc2Δ)

  • Include RNase/DNase treatment controls to distinguish direct protein interactions from nucleic acid-mediated associations

• Proximity-based labeling:

  • Generate BioID or TurboID fusion constructs with SPBC1271.07c

  • Use antibodies to validate expression and localization of fusion proteins

  • Compare biotinylated protein profiles between experimental conditions

• Antibody-based interaction mapping:

  • Perform systematic IP-MS studies under different growth conditions

  • Include nuclease treatments to distinguish direct from indirect interactions

  • Validate key interactions with reciprocal IPs

For TSC pathway specifically, examine interactions with:

• Rhb1 (fission yeast homolog of human RHEB)

• Tsc1/2 complex components

• Downstream effectors identified in suppressor screens

These approaches can help position SPBC1271.07c within the TSC signaling network and provide insights into its functional role.

How can computational antibody design improve SPBC1271.07c antibody specificity and affinity?

Computational approaches can significantly enhance SPBC1271.07c antibody development:

• Epitope prediction and optimization:

  • Utilize RosettaAntibodyDesign (RAbD) to model antibody-antigen interactions

  • Identify optimal epitopes based on surface accessibility and uniqueness

  • Design antibodies with improved specificity for regions that distinguish SPBC1271.07c from related acetyltransferases

• Structure-guided antibody engineering:

  • Apply the IsAb computational protocol to design antibodies with:

    • Enhanced binding affinity through optimized complementarity-determining regions (CDRs)

    • Improved specificity through targeted mutagenesis of key binding residues

    • Better stability and expression properties

These computational methods have revolutionized antibody design by enabling rational engineering of binding properties before experimental validation, potentially saving time and resources in developing improved SPBC1271.07c antibodies .

What are common causes of non-specific binding with SPBC1271.07c antibodies and how can they be addressed?

Non-specific binding in SPBC1271.07c antibody applications can arise from several sources:

• Cross-reactivity with related proteins:

  • SPBC1271 locus contains several related genes (e.g., SPBC1271.05c, SPBC1271.10c)

  • Solution: Perform cross-reactivity tests against purified related proteins

  • Mitigation: Use peptide regions unique to SPBC1271.07c for immunization

• Insufficient blocking:

  • Solution: Test alternative blocking agents (5% BSA, commercial blocking buffers)

  • Mitigation: Increase blocking time (2-3 hours) and concentration

• Secondary antibody issues:

  • Solution: Test secondary antibodies from different vendors

  • Mitigation: Include secondary-only controls

• Sample preparation concerns:

  • Solution: Add more protease inhibitors to prevent degradation products

  • Mitigation: Use freshly prepared samples and avoid freeze-thaw cycles

• Experimental table comparing blocking conditions:

  Blocking Agent	Concentration	Time	Background Reduction
  Non-fat milk	5%	1h	Moderate
  BSA	3%	1h	Variable
  Commercial blocker	1X	1h	Good
  Non-fat milk	5%	O/N	Excellent

When persistent non-specific binding occurs, consider using more stringent wash conditions (higher salt or detergent concentrations) and longer wash times.

How can I reconcile contradictory results between different batches of SPBC1271.07c antibodies?

Addressing batch variation requires systematic troubleshooting:

• Characterize batch differences:

  • Compare specificity using identical samples

  • Perform titration curves for each batch

  • Test both batches on known positive and negative controls

• Consider technical factors:

  • Standardize protocols rigorously between experiments

  • Use the same secondary antibody lot

  • Process samples identically (lysis method, protein quantification)

  • Run samples on the same gel when possible

• Validation approaches:

  • Use alternative detection methods (e.g., mass spectrometry)

  • Test with tagged versions of the protein

  • Consider epitope mapping to determine if batches recognize different regions

• Documentation and normalization:

  • Maintain detailed records of antibody lot numbers and performance

  • Use internal standards for quantitative comparisons

  • Apply appropriate normalization methods when analyzing data from different batches

When publishing results, clearly report which antibody batches were used and how their performance was validated to ensure reproducibility.

What statistical approaches are appropriate for analyzing co-localization data from immunofluorescence studies with SPBC1271.07c antibodies?

Rigorous statistical analysis of co-localization requires:

How can SPBC1271.07c antibodies be integrated into multi-omics approaches for studying acetyltransferase function?

Integrating SPBC1271.07c antibodies into multi-omics workflows offers comprehensive insights:

• Integrated IP-MS proteomics:

  • Use SPBC1271.07c antibodies for targeted proteomics to identify:

    • Interaction partners under different conditions

    • Post-translational modifications on SPBC1271.07c itself

    • Substrates of its acetyltransferase activity

  • Combine with SILAC or TMT labeling for quantitative comparisons

• ChIP-seq integration:

  • Map SPBC1271.07c genomic binding sites

  • Correlate with histone acetylation patterns (H3K9ac, H4K16ac)

  • Integrate with transcriptomics to connect binding with expression changes

• Cross-linking approaches:

  • Utilize SPBC1271.07c antibodies in cross-linking mass spectrometry (XL-MS)

  • Map protein interaction interfaces at amino acid resolution

  • Develop structural models of SPBC1271.07c complexes

This integrated approach can position SPBC1271.07c within cellular networks and reveal its regulatory role with unprecedented detail.

What special considerations apply when using SPBC1271.07c antibodies in genome-wide screening approaches?

When incorporating SPBC1271.07c antibodies into genome-wide screens:

• CUT&RUN/CUT&Tag optimization:

  • Test different cell permeabilization conditions

  • Optimize antibody concentrations (typically higher than for ChIP)

  • Include spike-in controls for normalization

  • Validate binding sites with orthogonal methods

• High-throughput immunofluorescence:

  • Standardize fixation and permeabilization for 96/384-well formats

  • Optimize primary and secondary antibody dilutions

  • Include appropriate controls in each plate

  • Develop robust automated image analysis pipelines

• IP-based genetic screens:

  • Use SPBC1271.07c antibodies to isolate complexes following genetic perturbations

  • Analyze enrichment/depletion patterns to identify genetic dependencies

  • Consider technical variation between immunoprecipitations

• Quality control metrics:

  Approach	Critical QC Parameters	Acceptance Criteria
  CUT&RUN	Fragment size distribution	150-250 bp peaks
  	Background in IgG controls	<5% of specific signal
  HT-IF	Z' factor	>0.5
  	Coefficient of variation	<20%
  IP-MS	Bait recovery	>50%
  	Reproducibility between replicates	r > 0.7

Maintaining rigorous quality control is essential when scaling up to genome-wide approaches to ensure reliable and interpretable results.

How can SPBC1271.07c antibody epitopes be optimized for detection of specific protein conformations or modifications?

Developing conformation or modification-specific SPBC1271.07c antibodies requires:

• Structural analysis prerequisites:

  • Predict or determine SPBC1271.07c structure (computational modeling or X-ray crystallography)

  • Identify conformational states relevant to function

  • Map potential post-translational modification sites

• Epitope design strategies:

  • For phospho-specific antibodies: Synthesize phosphopeptides corresponding to predicted modification sites

  • For conformation-specific antibodies: Design peptides that mimic specific structural elements

  • For acetylation-specific antibodies: Generate peptides with acetylated lysine residues

• Validation strategies:

  • Compare reactivity between wild-type and mutant proteins (e.g., phospho-null or phospho-mimetic)

  • Test antibody recognition under conditions that alter protein conformation

  • Perform competition assays with modified and unmodified peptides

These specialized antibodies can provide unique insights into SPBC1271.07c regulation and function that would be impossible with standard antibodies detecting only total protein levels.